# A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)

> **NCT00551447** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 616 (actual)

## Conditions studied

- Coronary Disease

## Interventions

- **DRUG:** MK0653, ezetimibe / Duration of Treatment: 27 Weeks
- **DRUG:** MK0733, simvastatin / Duration of Treatment: 27 Weeks
- **DRUG:** Comparator: simvastatin / Duration of Treatment: 27 Weeks

## Key facts

- **NCT ID:** NCT00551447
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2003-03
- **Final completion:** 2003-03
- **Target enrollment:** 616 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00551447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00551447, "A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00551447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*